Mercer Global Advisors
KROS icon

Mercer Global Advisors’s Keros Therapeutics KROS Stock Holding History

Mercer Global Advisors’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$296K Buy
27,684
+15,942
+136% +$178K ﹤0.01% 2822
2026
Q1 		$130K Buy
+11,742
New +$181K ﹤0.01% 2957

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Mercer Global Advisors's KROS Position: Q2 2026 in Review

Mercer Global Advisors increased its Keros Therapeutics (KROS) stake by 136% in Q2 2026, buying an estimated $178K and bringing the position to 27,684 shares worth $296K. The position accounts for ﹤0.01% of the portfolio, ranked #2822.

Mercer Global Advisors first reported a position in KROS in Q1 2026 and has held it in 2 quarters since. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Mercer Global Advisors held 27,684 shares of Keros Therapeutics worth $296K as of Q2 2026.
  • Mercer Global Advisors bought 15,942 Keros Therapeutics shares in Q2 2026, an estimated $178K.
  • Keros Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #2822 holding.
  • Mercer Global Advisors first reported a position in Keros Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.